Literature DB >> 10022911

Mutations of oncoprotein 18/stathmin identify tubulin-directed regulatory activities distinct from tubulin association.

N Larsson1, B Segerman, H M Gradin, E Wandzioch, L Cassimeris, M Gullberg.   

Abstract

Oncoprotein 18/stathmin (Op18) is a recently identified phosphorylation-responsive regulator of the microtubule (MT) system. It was originally proposed that Op18 specifically regulates dynamic properties of MTs by associating with tubulin, but it has subsequently been proposed that Op18 acts simply by sequestering of tubulin heterodimers. We have dissected the mechanistic action of Op18 by generation of two distinct classes of mutants. One class has interruptions of the heptad repeats of a potential coiled-coil region of Op18, and the other involves substitution at all four phosphorylation sites with negatively charged Glu residues. Both types of mutation result in Op18 proteins with a limited decrease in tubulin complex formation. However, the MT-destabilizing activities of the coiled-coil mutants are more severely reduced in transfected leukemia cells than those of the Glu-substituted Op18 derivative, providing evidence for tubulin-directed regulatory activities distinct from tubulin complex formation. Analysis of Op18-mediated regulation of tubulin GTPase activity and taxol-promoted tubulin polymerization showed that while wild-type and Glu-substituted Op18 derivatives are active, the coiled-coil mutants are essentially inactive. This suggests that Op18-tubulin contact involves structural motifs that deliver a signal of regulatory importance to the MT system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022911      PMCID: PMC84017          DOI: 10.1128/MCB.19.3.2242

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  24 in total

1.  Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin.

Authors:  A M Minotti; S B Barlow; F Cabral
Journal:  J Biol Chem       Date:  1991-02-25       Impact factor: 5.157

2.  Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics.

Authors:  U Marklund; N Larsson; H M Gradin; G Brattsand; M Gullberg
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

3.  Directional antisense and sense cDNA cloning using Epstein-Barr virus episomal expression vectors.

Authors:  R K Groger; D M Morrow; M L Tykocinski
Journal:  Gene       Date:  1989-09-30       Impact factor: 3.688

4.  The microtubule-destabilizing activity of metablastin (p19) is controlled by phosphorylation.

Authors:  S B Horwitz; H J Shen; L He; P Dittmar; R Neef; J Chen; U K Schubart
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

5.  Quantitative analysis of the expression and regulation of an activation-regulated phosphoprotein (oncoprotein 18) in normal and neoplastic cells.

Authors:  G Brattsand; G Roos; U Marklund; H Ueda; G Landberg; E Nånberg; P Sideras; M Gullberg
Journal:  Leukemia       Date:  1993-04       Impact factor: 11.528

6.  Serine 16 of oncoprotein 18 is a major cytosolic target for the Ca2+/calmodulin-dependent kinase-Gr.

Authors:  U Marklund; N Larsson; G Brattsand; O Osterman; T A Chatila; M Gullberg
Journal:  Eur J Biochem       Date:  1994-10-01

7.  Expression of oncoprotein 18 in human leukemias and lymphomas.

Authors:  G Roos; G Brattsand; G Landberg; U Marklund; M Gullberg
Journal:  Leukemia       Date:  1993-10       Impact factor: 11.528

8.  Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules.

Authors:  L D Belmont; T J Mitchison
Journal:  Cell       Date:  1996-02-23       Impact factor: 41.582

9.  The phenotype of a "Cdc2 kinase target site-deficient" mutant of oncoprotein 18 reveals a role of this protein in cell cycle control.

Authors:  U Marklund; O Osterman; H Melander; A Bergh; M Gullberg
Journal:  J Biol Chem       Date:  1994-12-02       Impact factor: 5.157

Review 10.  Effects of antimitotic agents on tubulin-nucleotide interactions.

Authors:  J J Correia
Journal:  Pharmacol Ther       Date:  1991-11       Impact factor: 12.310

View more
  7 in total

1.  Op18/stathmin mediates multiple region-specific tubulin and microtubule-regulating activities.

Authors:  N Larsson; B Segerman; B Howell; K Fridell; L Cassimeris; M Gullberg
Journal:  J Cell Biol       Date:  1999-09-20       Impact factor: 10.539

Review 2.  Mechanisms of Taxol resistance related to microtubules.

Authors:  George A Orr; Pascal Verdier-Pinard; Hayley McDaid; Susan Band Horwitz
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

3.  Model for stathmin/OP18 binding to tubulin.

Authors:  G Wallon; J Rappsilber; M Mann; L Serrano
Journal:  EMBO J       Date:  2000-01-17       Impact factor: 11.598

4.  The human T-cell leukemia virus type-1 tax oncoprotein dissociates NF-κB p65RelA-Stathmin complexes and causes catastrophic mitotic spindle damage and genomic instability.

Authors:  Aditi Malu; Tetiana Hutchison; Laçin Yapindi; Katie Smith; Katherine Nelson; Rachel Bergeson; Jordan Pope; Megan Romeo; Carolyn Harrod; Lee Ratner; Carine Van Lint; Robert Harrod
Journal:  Virology       Date:  2019-07-03       Impact factor: 3.616

5.  Phosphorylation disrupts the central helix in Op18/stathmin and suppresses binding to tubulin.

Authors:  M O Steinmetz; W Jahnke; H Towbin; C García-Echeverría; H Voshol; D Müller; J van Oostrum
Journal:  EMBO Rep       Date:  2001-06       Impact factor: 8.807

6.  Op18/stathmin caps a kinked protofilament-like tubulin tetramer.

Authors:  M O Steinmetz; R A Kammerer; W Jahnke; K N Goldie; A Lustig; J van Oostrum
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

7.  The catastrophe-promoting activity of ectopic Op18/stathmin is required for disruption of mitotic spindles but not interphase microtubules.

Authors:  P Holmfeldt; N Larsson; B Segerman; B Howell; J Morabito; L Cassimeris; M Gullberg
Journal:  Mol Biol Cell       Date:  2001-01       Impact factor: 4.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.